Table 1 Patient and tumor characteristics
Patients | Total |
|---|---|
n | 256 |
Mean age at diagnoses | 55 (18–86) |
Sex ratio (M/F) | 1.42 (150/106) |
Mean follow up after surgery (years) | 12.1 (0.8–42.7) |
Pre-operative data | |
Symptoms at diagnoses | |
Visual disorders | 157/234 (67%) |
Headache | 74/233 (32%) |
Fortuitous | 43/236 (18%) |
Adenoma size | |
Maximal tumor height (mm) | 28.6 (12–60) |
Microadenoma (< 1 cm) | 0 |
Macroadenoma (1–4 cm) | 133/148 (90%) |
Giant adenoma (> 4 cm) | 15/148 (10%) |
Patients with cavernous sinus invasion | 86/123 (70%) |
Post-operative data | |
Transsphenoidal/Transcranial surgery | 142/11 |
Residual tumor | 199/228 (87%) |
Mean maximal tumor height (mm) | 12.4 (0–50) |
Apoplexy | 24/230 (10%) |
Postoperative deficiencies | |
Corticotropic | 73/218 (35%) |
Thyrotropic | 108/220 (49%) |
Gonadotropic | 99/217 (46%) |
Panhypopuitarism | 39/221 (18%) |
Diabetes insipidus | 12/218 (6%) |
Normalization of preoperative visual disorders | |
Unknown | 47 (18.4%) |
Complete | 86 (33.6%) |
Partial | 42 (16.4%) |
No improvement | 16 (6%) |
None initial | 65 (25.4%) |
Patients with cavernous sinus invasion | 82/195 (42%) |
Tumor type | |
Unknown | 26 (10.2%) |
Nude cells | 93 (36.3%) |
ACTH | 13 (5%) |
FSH/LH | 106 (41.4%) |
GH | 0 (0%) |
PRL | 4 (1.6%) |
TSH | 1 (0.4%) |
Pluri-hormonal dominance | 13 (5.1%) |
Grades | |
Unknown | 128/256 |
1a | 26/128 (20%) |
1b | 24/128 (19%) |
2a | 40/128 (31%) |
2b | 38/128 (30%) |